Covid-19

Anticorpos para combater infecções virais: estratégias de desenvolvimento e progresso.

5 Jul, 2022 | 11:58h

Antibodies to combat viral infections: development strategies and progress – Nature Reviews Drug Discovery (se o acesso a este link for pago, tente este no PMC)

---

Diretrizes 2022 para o tratamento e a profilaxia do tromboembolismo venoso em pacientes com câncer, incluindo aqueles com COVID-19.

4 Jul, 2022 | 12:24h

2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19 – The Lancet Oncology

Conteúdos relacionados:

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy – Cochrane Library

American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer – Blood Advances

Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology – Journal of the National Comprehensive Cancer Network

Venous and Arterial Thromboembolism in Patients With Cancer: JACC: CardioOncology State-of-the-Art Review

---

Dois novos estudos mostram que a enoxaparina não tem benefício na tromboprofilaxia primária de pacientes ambulatoriais sintomáticos com COVID-19.

4 Jul, 2022 | 12:23h

Estudo 1: Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial – The Lancet Haematology

Estudo 2: Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial – The Lancet Haematology

Comentários:

Antithrombotic prophylaxis for symptomatic outpatients with COVID-19: less is consistently more – The Lancet Haematology

Antithrombotic Prophylaxis No Help in Outpatients With COVID — Two trials show no differences between patients who received enoxaparin vs standard of care – MedPage Today (necessário cadastro gratuito)

 

Comentário no Twitter (fio – clique para saber mais)

Early in the pandemic we wondered whether antithrombotic therapy in outpatients with #COVID19 would prevent #thrombosis ❓

Several trials were started globally and the ACTIV-4B trial was previously reported⬇️ https://t.co/Q15WcZwDIA

Now, we publish the OVID and ETHIC trials🧵

— The Lancet Haematology (@TheLancetHaem) June 30, 2022

 

---

Acurácia do teste rápido de antígeno vs. RT-PCR para infecção por SARS-CoV-2 em atletas universitários durante a prevalência da variante Ômicron.

4 Jul, 2022 | 12:18h

Accuracy of Rapid Antigen vs Reverse Transcriptase–Polymerase Chain Reaction Testing for SARS-CoV-2 Infection in College Athletes During Prevalence of the Omicron Variant – JAMA Network Open

 

Comentário no Twitter

In this case series of college athletes returning to campus during Omicron, rapid antigen tests were 63% sensitive, >99% specific for #COVID19, similar to previous strains and less well in detecting asymptomatic #SARSCoV2. @helixcardinal @stanford_ortho https://t.co/SBPr6NQ9Na

— JAMA Network Open (@JAMANetworkOpen) June 15, 2022

 

---

Estudo de coorte | Efetividade das vacinas Pfizer, Moderna e AstraZeneca contra desfechos graves de Covid-19 em um cenário de vacinação em massa de abrangência nacional.

4 Jul, 2022 | 12:16h

Effectiveness of BNT162b2, mRNA-1273, and ChAdOx1-S vaccines against severe covid-19 outcomes in a nationwide mass vaccination setting: cohort study – BMJ Medicine

 

Comentário no Twitter

🎉 Read our latest research article comparing the effectiveness of three #COVID vaccines against severe COVID outcomes. ▶️ https://t.co/uaQNgnDrrV#BMJMedicine #MedTwitter #openaccess pic.twitter.com/4oeG5d0j80

— BMJMedicine (@BMJMedicine) June 16, 2022

 

---

Quão comum é a COVID longa? Razões para os estudos darem respostas diferentes.

22 Jun, 2022 | 21:38h

How common is long COVID? Why studies give different answers – Nature

---

Diretriz provisória da OMS sobre o uso de vacinas contra COVID-19 atualizadas para as variantes.

21 Jun, 2022 | 13:12h

Interim statement on decision-making considerations for the use of variant updated COVID-19 vaccines – World Health Organization

Ver também: Interim statement on the composition of current COVID-19 vaccines – World Health Organization

 

Comentário no Twitter (fio – clique para saber mais)

Current #COVID19 vaccines provide high levels of protection against severe disease and death from all variants. They should continue to be used.

🆕 interim statement:https://t.co/bVzzx1HnG2 pic.twitter.com/CJlAJqFr3C

— World Health Organization (WHO) (@WHO) June 17, 2022

 

---

Estudo de caso-controle | Risco de COVID longa associado com variantes Delta vs. Ômicron do SARS-CoV-2.

21 Jun, 2022 | 13:06h

Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2 – The Lancet

Comunicado de imprensa: Long COVID risk less during Omicron compared to Delta, study finds – King’s College London

Comentários:

Expert reaction to study looking at long COVID prevalence associated with delta versus omicron variants of SARS-CoV-2 – Science Media Centre

Omicron less likely to lead to long COVID, study finds – CIDRAP

Covid-19: Long covid risk is lower with omicron than delta, researchers find – The BMJ

 

Comentário no Twitter

Substantial (~50-75%) reduction of #LongCovid with Omicron compared with Delta variant, magnitude influenced by age and time since vaccination @TheLancet https://t.co/shAzJn8WSj pic.twitter.com/bXoct0sXd1

— Eric Topol (@EricTopol) June 17, 2022

 

---

Estudo de consenso | Estabelecido de desfechos para a condição pós-COVID-19 para uso na prática clínica e em pesquisas.

21 Jun, 2022 | 13:05h

A core outcome set for post-COVID-19 condition in adults for use in clinical practice and research: an international Delphi consensus study – The Lancet Respiratory Medicine

Comunicado de imprensa: Key outcomes of Long COVID identified in international consensus study – King’s College London

Comentário convidado: Post-COVID-19 condition in children: a COS is urgently needed – The Lancet Respiratory Medicine

 

Comentário no Twitter

NEW POSITION PAPER—A core outcome set for post-COVID-19 condition in adults for use in clinical practice and research

From Daniel Munblit & co https://t.co/zAxQ1ww6bT pic.twitter.com/WIitohP3Xo

— The Lancet Respiratory Medicine (@LancetRespirMed) June 15, 2022

 

---

Dicas para Covid longa: cientistas se esforçam para desvendar o que determina os sintomas incapacitantes.

21 Jun, 2022 | 13:03h

Clues To Long Covid – Science

---